Skip to content
Sign in

CAPR · NASDAQ

Capricor Therapeutics (CAPR) Stock Price & Fundamentals

$328.52−0.17%−$0.57End-of-day price as of Oct 9, 2026

Capricor Therapeutics (CAPR) closed at $328.52 on Oct 9, 2026, down 0.17% from the previous close of $329.09.

Share price, past year

1Y +29.88%

52-week range $252.94 – $332.85. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$328.52
Sep 30, 2026$328.66
Aug 31, 2026$303.54
Jul 31, 2026$321.89
Jun 30, 2026$311.45
May 29, 2026$288.78
Apr 30, 2026$301.18
Mar 31, 2026$285.84
Feb 27, 2026$283.90
Jan 30, 2026$286.53
Dec 31, 2025$284.33
Nov 28, 2025$265.90
Oct 31, 2025$268.61

Key statistics

Market cap
$19.09B
P/E (TTM)
—
EPS (TTM)
−$2.45
Revenue (TTM)
—
Net income (TTM)
−$129.42M
Shares outstanding
58.1M
Dividend yield
—
52-week range
$252.94 – $332.85

Capricor Therapeutics's market cap is $19.09B, based on a share price of $328.52 and 58.1M shares outstanding as of Jun 30, 2026.

Financials

Capricor Therapeutics reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.

Capricor Therapeutics reported a net loss of $105.04M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Capricor Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$0.00−100.0%−$105.04M—−$2.26−$72.72M
FY2024ended Dec 31, 2024$22.27M−11.6%−$40.47M−181.7%−$1.15−$41.16M
FY2023ended Dec 31, 2023$25.18M+886.8%−$22.29M−88.5%−$0.83−$26.91M
FY2022ended Dec 31, 2022$2.55M+941.9%−$29.02M−1,137.4%−$1.18$2.92M
FY2021ended Dec 31, 2021$244.90K−21.1%−$20.02M−8,175.9%−$0.87−$18.01M
FY2020ended Dec 31, 2020$310.25K−69.1%−$13.66M−4,401.9%−$0.88−$10.60M
FY2019ended Dec 31, 2019$1.01M−39.9%−$7.64M−760.4%−$2.06−$6.82M
FY2018ended Dec 31, 2018$1.67M−37.3%−$15.19M−908.9%−$0.52−$14.18M
FY2017ended Dec 31, 2017$2.67M−33.3%$2.43M91.2%$0.09−$14.26M
FY2016ended Dec 31, 2016$4.00M—−$18.81M−470.3%−$1.01−$14.65M
Capricor Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q4 FY2024ended Dec 31, 2024$11.13M−$7.12M−$0.11
Q3 FY2024ended Sep 30, 2024$2.26M−$12.56M−$0.38
Q2 FY2024ended Jun 30, 2024$3.97M——
Q1 FY2024ended Mar 31, 2024$4.91M——
Q4 FY2023ended Dec 31, 2023$12.09M——
Q3 FY2023ended Sep 30, 2023$6.19M——
Q2 FY2023ended Jun 30, 2023$3.92M——
Q1 FY2023ended Mar 31, 2023$2.99M——

Company profile

Name
Capricor Therapeutics, Inc.
Ticker
CAPR
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
10865 Road To The Cure, Suite 150, San Diego, CA 92121
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001133869

Recent SEC filings

Frequently asked questions

What is Capricor Therapeutics's stock price?

Capricor Therapeutics (CAPR) closed at $328.52 on Oct 9, 2026, down 0.17% from the previous close of $329.09.

What is Capricor Therapeutics's market cap?

Capricor Therapeutics's market cap is $19.09B, based on a share price of $328.52 and 58.1M shares outstanding as of Jun 30, 2026.

How much revenue does Capricor Therapeutics make?

Capricor Therapeutics reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.

Does Capricor Therapeutics pay a dividend?

Capricor Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Capricor Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures